ATOS Stock Forecast: Atossa Therapeutics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Atossa Therapeutics, Inc. is $22. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 22 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Atossa Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (63): Analysts have, on balance, been raising their forecasts.
Momentum (3): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
ATOS stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ATOS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 1 Oct 2026 | Ascendiant Capital | Maintains | Buy | $24 → $25 |
| 7 July 2026 | Rodman & Renshaw | Initiates | Buy | $12 |
| 10 Apr 2026 | Ascendiant Capital | Maintains | Buy | — |
| 26 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 8 Dec 2025 | Ascendiant Capital | Maintains | Buy | — |
| 22 Sept 2025 | Ascendiant Capital | Maintains | Buy | — |
| 6 June 2025 | Ascendiant Capital | Maintains | Buy | — |
| 5 June 2025 | Craig-Hallum | Initiates | Buy | — |
| 21 Apr 2025 | Ascendiant Capital | Maintains | Buy | — |
| 26 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 9 Dec 2024 | Ascendiant Capital | Maintains | Buy | — |
| 13 Nov 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 5 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 31 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 Sept 2024 | Ascendiant Capital | Maintains | Buy | — |
| 12 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ATOS.
This page is one stock. Monday covers all of them.
ATOS appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
ATOS vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Atossa Therapeutics, Inc. returned −85.8% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
ATOS analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 0.7×
- EV / EBITDA
- —
Cheaper than 79% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −96.9%
- Return on assets
- −53.1%
- Dividend yield
- —
Higher than 14% of US stocks
Higher than 7% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Atossa Therapeutics, Inc. has a market value of $16.0M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$37.7M.
Free cash flow in the twelve months to 30 June 2026: −$35.8M.
Atossa Therapeutics, Inc. employs 16 people.
Data provided by Twelve Data
ATOS and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at ATOS’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Atossa Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about ATOS
What is the ATOS stock price forecast for 2026-2027?
The median 12-month analyst price target for Atossa Therapeutics, Inc. is $22, with estimates ranging from $10 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ATOS stock a buy right now?
Of the 2 analysts covering Atossa Therapeutics, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Atossa Therapeutics, Inc. 22 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ATOS?
As at 21 Nov 2026, Atossa Therapeutics, Inc. ranks 22 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (63 of 100).
Will ATOS stock go up?
No one can know that. What the data says: the median 12-month target from 2 analysts is $22, and Ticker Nerd's factor model ranks Atossa Therapeutics, Inc. 22 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ATOS stock forecast for 2030?
No analyst covering Atossa Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ATOS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $25 over the next 12 months.
How has ATOS stock performed over the past year?
Atossa Therapeutics, Inc. returned -85.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Atossa Therapeutics, Inc. do?
Atossa Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for breast cancer and other breast health conditions. The company’s work centers on oncology, with an emphasis on hormone-driven disease areas and related unmet medical needs.
About Atossa Therapeutics, Inc.
Atossa Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for breast cancer and other breast health conditions. The company’s work centers on oncology, with an emphasis on hormone-driven disease areas and related unmet medical needs. Its current pipeline includes investigational medicines and therapeutic programs designed to address breast cancer prevention and treatment, as well as selected rare diseases where estrogen-related biology may be relevant. Atossa Therapeutics also advances diagnostic capabilities connected to breast health, supporting a broader approach to disease management. Based in Seattle, Washington, the company operates within the biotechnology sector and plays a role in translating research into potential treatment options for women’s health and cancer care.
CEO Dr. Steven C. Quay FCAP, M.D., Ph.D. · 16 employees · United States · https://www.atossatherapeutics.com